Literature DB >> 9773251

Heparin-induced thrombocytopenia and thrombosis.

G Arepally1, D B Cines.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9773251     DOI： 10.1007/BF02737634

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN： 1080-0549            Impact factor:   8.667


× No keyword cloud information.
  89 in total

1.  Arterial embolism occurring during systemic heparin therapy.

Authors:  R E WEISMANN; R W TOBIN
Journal:  AMA Arch Surg       Date:  1958-02

2.  A bioluminescent adenosine nucleotide release assay for the diagnosis of heparin-induced thrombocytopenia.

Authors:  J M Teitel; P Gross; P Blake; M B Garvey
Journal:  Thromb Haemost       Date:  1996-09       Impact factor: 5.249

Review 3.  Heparin-induced thrombocytopenia.

Authors:  B H Chong
Journal:  Blood Rev       Date:  1988-06       Impact factor: 8.250

4.  Pregnancy complicated by heparin associated thrombocytopenia: management by a prospectively in vitro selected heparinoid (Org 10172).

Authors:  A Greinacher; T Eckhardt; J Mussmann; C Mueller-Eckhardt
Journal:  Thromb Res       Date:  1993-07-15       Impact factor: 3.944

5.  Treatment of heparin-associated thrombocytopenia and thrombosis with low molecular weight heparin (CY 216).

Authors:  J Leroy; M H Leclerc; B Delahousse; C Guérois; P Foloppe; Y Gruel; F Toulemonde
Journal:  Semin Thromb Hemost       Date:  1985-07       Impact factor: 4.180

6.  Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4.

Authors:  J G Kelton; J W Smith; T E Warkentin; C P Hayward; G A Denomme; P Horsewood
Journal:  Blood       Date:  1994-06-01       Impact factor: 22.113

7.  Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells.

Authors:  G P Visentin; S E Ford; J P Scott; R H Aster
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

8.  Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia.

Authors:  F Schiele; A Vuillemenot; P Kramarz; Y Kieffer; T Anguenot; Y Bernard; J P Bassand
Journal:  Am J Hematol       Date:  1995-09       Impact factor: 10.047

9.  Plasmapheresis in the management of heparin-associated thrombocytopenia with thrombosis.

Authors:  S Nand; J A Robinson
Journal:  Am J Hematol       Date:  1988-07       Impact factor: 10.047

Review 10.  Heparin-induced thrombocytopenia.

Authors:  T E Warkentin; J G Kelton
Journal:  Annu Rev Med       Date:  1989       Impact factor: 13.739
View more
  5 in total

1.  Rational design and characterization of platelet factor 4 antagonists for the study of heparin-induced thrombocytopenia.

Authors:  Bruce S Sachais; Ann H Rux; Douglas B Cines; Serge V Yarovoi; Lee I Garner; Stephen P Watson; Jillian L Hinds; John J Rux
Journal:  Blood       Date:  2012-03-27       Impact factor: 22.113

2.  PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model.

Authors:  Michael P Reilly; Uma Sinha; Pierrette André; Scott M Taylor; Yvonne Pak; Francis R Deguzman; Nisha Nanda; Anjali Pandey; Moritz Stolla; Wolfgang Bergmeier; Steven E McKenzie
Journal:  Blood       Date:  2010-11-18       Impact factor: 22.113

3.  Antimicrobial activity of a novel catheter lock solution.

Authors:  Chirag B Shah; Marc W Mittelman; J W Costerton; Stephen Parenteau; Michael Pelak; Richard Arsenault; Leonard A Mermel
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

4.  Heparin-induced thrombocytopenia in the pediatric population: a review of current literature.

Authors:  Niyati H Vakil; Abir O Kanaan; Jennifer L Donovan
Journal:  J Pediatr Pharmacol Ther       Date:  2012-01

Review 5.  Mechanisms of Immunothrombosis in Vaccine-Induced Thrombotic Thrombocytopenia (VITT) Compared to Natural SARS-CoV-2 Infection.

Authors:  Dennis McGonagle; Gabriele De Marco; Charles Bridgewood
Journal:  J Autoimmun       Date:  2021-05-19       Impact factor: 7.094
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.